Go Pro
→ The #1 stock to own BEFORE December 8th (From Behind the Markets) (Ad)tc pixel Free FNCH Stock Alerts

Finch Therapeutics Group (FNCH) Competitors

Finch Therapeutics Group logo
$7.30 0.00 (0.00%)
As of 09/24/2026
Compare

FNCH vs. AGFY, SCLX, GRCE, SCYX, and IXHL

Should you buy Finch Therapeutics Group stock or one of its competitors? Finch Therapeutics Group's main competitors and comparable companies include Agrify (AGFY), Scilex (SCLX), Grace Therapeutics (GRCE), SCYNEXIS (SCYX), and Incannex Healthcare (IXHL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Finch Therapeutics Group compare to Agrify?

Agrify (NASDAQ:AGFY) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

6.0% of Agrify shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 2.2% of Agrify shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Agrify has higher revenue and earnings than Finch Therapeutics Group. Agrify is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agrify$12.26M3.76-$41.75M-$22.65N/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

In the previous week, Agrify had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Agrify and 0 mentions for Finch Therapeutics Group. Agrify's average media sentiment score of 0.67 beat Finch Therapeutics Group's score of 0.00 indicating that Agrify is being referred to more favorably in the media.

Company Overall Sentiment
Agrify Positive
Finch Therapeutics Group Neutral

Agrify has a beta of 9.96, indicating that its stock price is 896% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Finch Therapeutics Group has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Finch Therapeutics Group's return on equity of -69.14% beat Agrify's return on equity.

Company Net Margins Return on Equity Return on Assets
Agrify-424.11% -185.90% -72.67%
Finch Therapeutics Group N/A -69.14%-26.92%

Summary

Finch Therapeutics Group beats Agrify on 7 of the 12 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Scilex?

Finch Therapeutics Group (NASDAQ:FNCH) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Scilex had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Scilex and 0 mentions for Finch Therapeutics Group. Scilex's average media sentiment score of 1.82 beat Finch Therapeutics Group's score of 0.00 indicating that Scilex is being referred to more favorably in the news media.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Scilex Very Positive

Finch Therapeutics Group has higher earnings, but lower revenue than Scilex. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Scilex$30.25M1.37-$358.73M-$49.70N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Finch Therapeutics Group has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Scilex -1,414.57%N/A -147.00%

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 4.5% of Scilex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Scilex has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Summary

Scilex beats Finch Therapeutics Group on 8 of the 13 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Grace Therapeutics?

Finch Therapeutics Group (NASDAQ:FNCH) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Finch Therapeutics Group has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Grace Therapeutics' return on equity of -36.11% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Grace Therapeutics N/A -36.11%-34.39%

Grace Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Grace TherapeuticsN/AN/A-$7.79M-$1.18N/A

Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 183.02%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Grace Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Grace Therapeutics had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Grace Therapeutics and 0 mentions for Finch Therapeutics Group. Grace Therapeutics' average media sentiment score of 1.31 beat Finch Therapeutics Group's score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Grace Therapeutics Positive

Summary

Grace Therapeutics beats Finch Therapeutics Group on 8 of the 13 factors compared between the two stocks.

How does Finch Therapeutics Group compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Finch Therapeutics Group has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
SCYNEXIS-41.79% -44.15% -32.61%
Finch Therapeutics Group N/A -69.14%-26.92%

SCYNEXIS has higher revenue and earnings than Finch Therapeutics Group. SCYNEXIS is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SCYNEXIS$20.60M2.12-$8.61M-$2.09N/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

SCYNEXIS has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

In the previous week, SCYNEXIS had 4 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for SCYNEXIS and 0 mentions for Finch Therapeutics Group. SCYNEXIS's average media sentiment score of 0.64 beat Finch Therapeutics Group's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.

Company Overall Sentiment
SCYNEXIS Positive
Finch Therapeutics Group Neutral

SCYNEXIS presently has a consensus price target of $33.00, indicating a potential upside of 651.71%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 4.1% of SCYNEXIS shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

SCYNEXIS beats Finch Therapeutics Group on 10 of the 15 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Incannex Healthcare?

Finch Therapeutics Group (NASDAQ:FNCH) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Incannex Healthcare has a consensus price target of $18.00, suggesting a potential upside of 442.17%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Incannex Healthcare
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Incannex Healthcare had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Incannex Healthcare and 0 mentions for Finch Therapeutics Group. Incannex Healthcare's average media sentiment score of 1.82 beat Finch Therapeutics Group's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Incannex Healthcare Very Positive

Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.97, suggesting that its stock price is 597% more volatile than the broader market.

Finch Therapeutics Group's return on equity of -69.14% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Incannex Healthcare N/A -81.01%-76.11%

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Incannex Healthcare has higher revenue and earnings than Finch Therapeutics Group. Incannex Healthcare is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Incannex Healthcare$90K441.56-$46.88M-$1.55N/A

Summary

Incannex Healthcare beats Finch Therapeutics Group on 9 of the 14 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FNCH vs. The Competition

Export
MetricFinch Therapeutics GroupPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$11.72M$12.54B$7.27B$13.10B
Dividend YieldN/A2.63%2.52%13.51%
P/E Ratio-0.83789.85274.4125.75
Price / SalesN/A748.37618.3786.14
Price / CashN/A91.6479.2352.93
Price / Book0.5110.5110.436.30
Net Income-$74.75M$2.81B$3.49B$359.77M
7 Day PerformanceN/A-0.96%-1.25%-0.23%
1 Month PerformanceN/A-2.99%-4.67%-3.88%
1 Year Performance-40.55%1.06%15.06%5.35%

Finch Therapeutics Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FNCH
Finch Therapeutics Group
N/A$7.30
flat		N/AN/A$11.72MN/AN/A190
AGFY
Agrify
N/A$22.77
+9.1%		N/A-39.0%$45.61M$12.26MN/A140
SCLX
Scilex
0.5386 of 5 stars		$5.29
-1.6%		N/A-83.1%$44.99M$31.61MN/A34
GRCE
Grace Therapeutics
2.2442 of 5 stars		$2.13
-0.2%		$6.00
+182.4%		-31.2%$44.70MN/AN/A5
SCYX
SCYNEXIS
2.8477 of 5 stars		$4.48
+0.7%		$33.00
+636.6%		-49.2%$44.58M$20.60MN/A29

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FNCH) was last updated on 9/26/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...
Decentralized Masters | Sponsoredtc pixel